Partner Therapeutics buys global rights for an immuno-stimulant from Sanofi

US cancer startup Partner Therapeutics, Inc. (PTx) announced that it has acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.

Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections. Leukine is used to treat or prevent severe and life-threatening infections and is the only immune modulator approved by the FDA for the treatment of acute myelogenous leukemia (AML) in older patients and for use in both allogeneic and autologous bone marrow transplantation.

In connection with the acquisition of Leukine, PTx will also acquire a dedicated manufacturing facility in Lynnwood, Washington, USA. The facility is a state of the art biologics manufacturing plant that was certified for commercial production in 2012.  The Lynnwood facility will serve as the core manufacturing and supply chain center for PTx’s operations.

Leukine is the only FDA-approved recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF). It has been demonstrated to promote growth and activation of monocytes, macrophages, neutrophils and dendritic cells.

PTx will support the development of Leukine for new indications.  The product is being tested in a diverse set of clinical trials for its potential to improve survival and reduce adverse events in combination with leading immuno-oncology therapies.

PTx, based in Boston, is an integrated commercial stage biotech company focused on the development and commercialization of therapeutics that improve health and economic outcomes in the treatment of cancer.

GMP news
Pharmaceutical industry News and events. Technology transfer and contract manufacturing of medicines.